OC-0544: Heterogeneous FDG-guided dose escalation of locally advanced NSCLC, the NARLAL2 phase III trial. (April 2016) - Moeller, D.S.; Hoffmann, L.; Lutz, C.M.; Nielsen, T.B.; Brink, C.; Appelt, A.L.; Lund, M.D.; Nielsen, M.S.; Ottosson, W.; Khalil, A.A.; Knap, M.M.; Hansen, O.; et al.